Type
Internal restructuring
Country
Denmark
Region
Københavns amt;
Location of affected unit(s)
Bagsværd
Sector
Manufacturing
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.20 - Manufacture of pharmaceutical preparations

370 jobs
Number of planned job losses
Job loss
Announcement Date
18 September 2018
Employment effect (start)
1 October 2018
Foreseen end date

Description

In September 2018, the Danish multi-national pharmaceutical company announced that 370 employees in Denmark will be made redundant as part of a comprehensive restructuring. Additionally, 30 employees in China within reseach and development will be laid off. Novo Nordisk wants to focus on developing pharmaceuticals for a wider spectrum of chronical diseases. The round of lay-offs aims to free up resources to strengthen other areas.

There is no information about the time schedule of the lay-offs. Earlier restructuring in Bagsværd took place in 2016, when Novo Nordisk made 500 employees redundant. 

In Denmark, Novo Nordisk employs about 17,300 people. World wide, the company holds 42,000 full-time equivalent positions in 75 countries. 


Sources

Citation

Eurofound (2018), Novo Nordisk, Internal restructuring in Denmark, factsheet number 95567, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/95567.